Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Innovations in Clinical Neuroscience|June 20, 2019
Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple SclerosisLaetitia Pouzol, Luca Piali, Claude Ca Bernard, et al.
European Journal of Immunology|February 13, 2001
MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway,I M Medana, A Gallimore, A Oxenius, et al.
Blood|April 9, 2004
Do thymically and strictly extrathymically developing T cells generate similar immune responses?Marie-Eve Blais, Gwladys Gérard, Marianne M Martinic, et al.
Frontiers in Pharmacology|November 22, 2021
CXCR7 Antagonism Reduces Acute Lung Injury PathogenesisLaetitia Pouzol, Anna Sassi, Nadège Baumlin, et al.
Journal of Autoimmunity|October 12, 2010
Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesisMarianne M Martinic, Christoph Huber, Ken Coppieters, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 17, 2021
ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseasesLaetitia Pouzol, Nadège Baumlin, Anna Sassi, et al.
The Journal of Experimental Medicine|October 13, 2006
Resolution of a chronic viral infection after interleukin-10 receptor blockadeMette Ejrnaes, Christophe M Filippi, Marianne M Martinic, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 17, 2017
The Bacterial Peptidoglycan-Sensing Molecules NOD1 and NOD2 Promote CD8+ Thymocyte SelectionMarianne M Martinic, Irina Caminschi, Meredith O'Keeffe, et al.
Neurochemical Research|May 31, 2024
ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating EffectsLaetitia Pouzol, Anna Sassi, Mélanie Tunis, et al.
Clinical and Experimental Immunology|July 17, 2023
Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetesUrs Christen, Laetitia Pouzol, Mélanie Tunis, et al.
Pageof 3